ViewMind is a digital health and artificial intelligence company that provides clinically validated solutions for precision assessment of neurocognitive disorders.
ViewMind’s technology is based on ocular digital phenotyping that measures the state of 16 cognitive domains and 19 brain related brain regions. It delivers groundbreaking levels of accuracy and correlates with biomarkers, neuroimaging and EEG.
ViewMind’s fundamental technology is based on research and development led by Dr. Gerardo Fernandez, ViewMind’s Chief Science Officer and Co-founder. ViewMind developed a technology that phenotypes eye movement responses to visual stimuli and the functioning of specific cognitive domains and related areas of the brain.
ViewMind is collaborating with various academic institutions, hospitals, research facilities, key opinion leaders, and pharmaceutical companies to test and iterate on this breakthrough technology.
We are interested in additional partnerships for:
Founder and Managing Partner of R3i Ventures, a seed-stage VC Fund based in Luxembourg, Singapore and Silicon Valley.
Founder and managing partner of CITES, a deeptech early stage VC fund.
Professor, Director and founder of the Antioquia Neuroscience Group at the University of Antioquia in Medellín, Colombia. Dr. Lopera is one of the world’s leading specialists on Alzheimer’s & neurodegenerative disorders.
Dr. Greenleaf is a Stanford University research neuroscientist and medical product developer and one the world’s leading authorities in the use of virtual reality technology in healthcare.
A pharmaceutical executive with over 20 years of experience in global medical roles, including Novo Nordisk, AstraZeneca and Zealand Pharma.